Hadassah

Thousands of Druze Villagers Mobilize to Save Baby’s Life

Thursday, Mar 8 2018

The knowledge that four-month-old Husam urgently needed a bone marrow transplant to save his life brought out tens of thousands of community members from the Druze village of Issifiya and neighboring areas to see if their bone marrow would be a match.

This unprecedented, large-scale bone marrow campaign was conducted in the Druze villages of the Galilee and the Golan Heights, establishing, for the first time, a Druze data base within the Bone Marrow Registry at the Hadassah Medical Organization. The campaign, led by Ofra Elkouby, Director of Hadassah’s Bone Marrow Registry, was carried out with full cooperation of Mufid Mar'i, Chair of the forum comprising the heads of the Druze local councils.

“This operation,” commented Ms. Elkouby, “was a demonstration of unity and support for the Druze people, and not just in the Druze sector.”

Baby Husam’s grandfather was the first Druze officer in Israel’s National Defense Forces. 

The Bone Marrow Registry at Hadassah is the second largest in Israel. The samples in its data base come from the general public and are used to locate donors for patients both in Israel and abroad who require bone marrow transplants. 

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More